MedTrace Logo

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

NCT02872025 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-01-30

No results posted yet for this study

Summary

This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.

Conditions

  • Carcinoma, Intraductal, Noninfiltrating

Interventions

DRUG

Pembrolizumab

Injected intralesionally

BIOLOGICAL

Intralesional mRNA 2752

Injected intralesionally

Sponsors & Collaborators

Principal Investigators

  • Laura Esserman, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-12
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872025 on ClinicalTrials.gov